<DOC>
	<DOCNO>NCT00072098</DOCNO>
	<brief_summary>RATIONALE : Inserting interleukin-12 gene person 's cancer cell may make body build immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose interleukin-12 gene injected tumor patient liver metastasis secondary colorectal cancer .</brief_summary>
	<brief_title>Interleukin-12 Gene Treating Patients With Liver Metastases Secondary Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity maximum tolerate dose intratumoral adenoviral vector-delivered interleukin-12 gene patient liver metastasis secondary colorectal cancer . - Determine tumor response patient treat regimen . - Determine immune response patient treat regimen .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirmed* colorectal adenocarcinoma metastatic liver Solitary multiple metastatic tumor liver Metastatic involvement liver great 40 % estimate liver volume NOTE : *Must hepatic tumor designate study injection Metastatic liver tumor must bidimensionally measurable CT scan MRI At least 1 metastatic liver tumor measure least 2.0 cm must visualize ultrasound ( US ) accessible USguided percutaneous injection Extrahepatic metastasis allow No prior current ascites Ineligible hepatic resection PATIENT CHARACTERISTICS : Age Adult Performance status Karnofsky 70100 % Life expectancy At least 16 week Hematopoietic Granulocyte count least 1,500/mm^3 Hemoglobin least 9.0 g/dL Platelet count least 100,000/mm^3 Hepatic No clinical evidence severe liver disease ( e.g. , portosystemic encephalopathy ) PT great 14 second Bilirubin great 2.0 time upper limit normal ( ULN ) Transaminases great 2.5 time ULN Renal Creatinine great 1.5 mg/dL OR Creatinine clearance least 45 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception least 2 month study participation HIV negative No active infection No concurrent serious medical illness No malignancy within past 5 year except inactive nonmelanoma skin cancer , carcinoma situ cervix , grade 1 papillary bladder cancer Oriented rational Weight least 30 kg PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) Endocrine therapy At least 2 month since prior corticosteroid Radiotherapy Not specify Surgery Not specify Other At least 2 month since prior systemic immunosuppressive drug No concurrent immunosuppressive drug No concurrent anticoagulant therapy heparin warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
</DOC>